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Skin Graft Rejection Suppressed by Vaccination with T Cells 
In this issue, Mar&a Perez, Richard Edelson, Liliane Laroche, and 
Carole Berger of Yale University School of Medicine in New 
Haven, Connecticut, and Columbia University in New York City 
report the discovery of a new type of vaccination that may be useful 
for preventing unwanted immune responses, such as those causing 
the rejection of transplanted organs or autoimmune diseases. Perez, 
Edelson, and their colleagues have shown that they can take the T 
cells that mediate such an undesired immune attack, in this case the 
rejection of skin grafts by mice, and effectively turn the cells on 
themselves, so that they cause the immune system to suppress the 
responses that would otherwise destroy the skin grafts. The method 
may be applicable for treating autoimmune diseases, such as sys- 
temic lupus erythematosus, pemphigus vulgaris, and multiple scle- 
rosis, as well as for inhibiting the rejection of transplanted organs. 
The current study is an outgrowth of previous work in which 
Edelson and his colleagues devised a new therapy for cutaneous 
T-cell lymphoma. In this therapy, blood lymphocytes are first re- 
covered from the patients. These cells contain a high proportion of 
the T cells that are growing out of control and causing the lym- 
phoma. The lymphocytes are inactivated by exposing them to 8- 
methoxypsoralen (8-MOP) and ultraviolet light A (UVA) and re- 
turned to the patients. This treatment causes the lymphoma to 
regress, apparently by triggering an immune attack on the lym- 
phoma cells. “The T cells that have been so exposed (to 8-MOP and 
UVA irradiation) appear to induce an immune response against 
themselves and others like them,” Edelson says. 
Perez, Edelson, and their colleagues devised a mouse skin-graft 
model to test whether the T-cell therapy works in the way postu- 
lated. They prepared cells from the spleens of mice that were reject- 
ing a foreign skin graft. The spleen cells, which should be enriched 
in the T cells causing the rejection, were also inactivated by ex os- 
ing them to 8-MOP and UVA, and then injected into mice o P the 
same strain as the cell donors. These mice, when subsequently given 
skin grafts, proved to be tolerant to the foreign tissue, even though it 
was of the same genetic type as the grafts that originally elicited 
immune rejection. “All of these animals retained the grafts past 15 
days,” Perez says, “while all the controls rejected theirs in seven 
days.” 
In vitro assays of immune cell function in the mice that had 
received the treated spleen cells suggested that the animals were 
making immune cells that suppressed the graft rejection response. 
This is in accord with the Edelson group’s hypothesis about how the 
therapy for cutaneous T-cell lymphoma works. Lymphocytes that 
have been exposed to 8-MOP and UVA apparently elicit the pro- 
duction of suppressor cells that act in the one case against the lym- 
phoma T cells and in the other against the T cells that elicit skin 
graft rejection. 
Edelson notes that T-cell vaccinations comparable to those used 
for treating cutaneous T-cell lymphoma are beginning to be tested 
as therapies for a variety of autoimmune diseases that are thought to 
be caused by aberrant T-cell activities. The current study, he says, 
“doesn’t answer all the questions, but it demonstrates a scientific 
basis for the clinical responses being observed.” 
New Clues to How Ultraviolet Light Causes Tanning 
“Our goal in these studies is to try to understand how the signal 
from ultraviolet light is transduced into a chemical signal that re- 
sults in melanization,” says John Pawelek of Yale University School 
of Medicine in New Haven, Connecticut. The changes that lead to 
the tanning of skin had been thought to be a response to the cellular 
injury caused by ultraviolet light. But, Pawelek explains, those 
changes occur in such a highly reproducible manner-the same 
way every time for everybody -that tanning appears to be more 
closely regulated than it would be if it were only a generalized 
response to injury. 
In this issue, Pawelek and Jean Bolognia and Marilyn Murray, 
also of Yale, provide new evidence in support of the idea that mel- 
anization in response to ultraviolet B (UVB) irradiation is regulated 
in a specific fashion, through the activity of melanocyte stimulating 
hormone (MSH). The researchers have found that mouse mela- 
noma cells acquire an increased ability to bind MSH after they are 
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exposed to UVB radiation. This suggests that the radiation increases 
the activity of the MSH receptors in the cells, thereby increasing 
their responsiveness to the hormone. MSH has activities consistent 
with its proposed ability to mediate tanning. For example, it stimu- 
lates melanin production and the proliferation of cultured mela- 
noma cells. 
The Yale workers postulated that if UVB radiation works 
through MSH, the two agents should potentiate each other’s effects 
in promoting melanin synthesis in the skin. That is exactly what the 
researchers found. In both mouse and guinea-pig skin, the two 
agents together gave a much greater stimulation of melanin synthe- 
sis than either of them separately. 
How UVB radiation might increase MSH receptor activity in 
melanocytes is currently unclear. Pawelek and his colleagues are 
currently investigating the hypothesis that the skin pigment cells 
may have a light-detecting system similar to the one the eye uses for 
converting light energy to nerve-cell activity. Melanin absorbs ul- 
traviolet light and, Pawelek speculates, may possibly serve as the 
light-collecting pigment for melanocytes, much as rhodopsin per- 
forms this function in retinal cells. 
Monofunctional Psoralens Also Affect the Skin’s Immune Cells 
The common PUVA treatment for psoriasis, which combines a 
psoralen such as 8-methoxypsoralen (8-MOP) with ultraviolet A 
(UVA) irradiation, has a number of unwanted side effects. It can be 
toxic for skin cells, for example, and causes a suppression of cutane- 
ous immune responses that may contribute to the increased risk of 
skin cancer seen in patients who have received PUVA treatments. In 
an effort to reduce these side effects, dermatologists have begun 
replacing 8-MOP and other bifunctional psoralens with monofunc- 
tional psoralens, which are much less cytotoxic. (Bifunctional pso- 
ralens can attach to two DNA strands at a time, thereby crosslinking 
the strands, whereas a monofunctional psoralen attaches to just one 
DNA strand.) 
In this issue, however, Joseph Alcalay, Corazon Bucana, and 
Margaret Kripke of the University of Texas M. D. Anderson Cancer 
Center in Houston, report that monofunctional psoralens, despite 
their lesser cytotoxicity, have effects on the immune cells of the skin 
that are similar to those of the bifunctional psoralens. “Just because 
something doesn’t have cytotoxicity, it doesn’t mean that we don’t 
have to worry about what it does to immune cells,” Kripke says. 
The M. D. Anderson group exposed mouse skin to either UVA 
radiation plus 8-MOP or to UVA radiation plus the monofunction 
psoralen angelicin. As expected, the skin of the animals treated with 
8-MOP showed a great deal of phototoxic damage, whereas the skin 
of the animals who got angelicin showed little or none. Neverthe- 
less, both drugs caused comparable losses of the cell surface markers 
carried by the skin’s immune cells. The loss occurred more slowly 
with angelicin, but Kripke says, “If you give repeated treatments, 
the outcome is the same.” 
The loss of the immune cell markers does not necessarily mean 
that the cells themselves have lost their function or disappeared 
from the skin, Kripke notes. The Texas group is currently deter- 
mining what the functional consequences of the psoralen exposures 
might be. Psoriasis patients often receive repeated PUVA treat- 
ments, however, and the results so far suggest that monofunctional 
psoralens offer no advantage over the bifunctional variety, at least 
with regard to preserving the skin’s immune cells. 
Basement Membrane Disruption May Facilitate Invasion by Melanomas 
The ability of malignant melanomas to spread may be facilitated by 
a loss of basement membrane components surrounding the cancer 
cells. In this issue, Christian Schmoeckel, Wilhelm Stolz, and 
Thomas Krieg of the University of Munich; Lynn Sakai and Robert 
Burgeson of the Shriners Hospital for Crippled Children in Port- 
land, Oregon; and Rupert Timpl of the Max Planck Institute for 
Biochemistry in Martinsried, Germany, report that nonmalignant 
nevi and melanomas that are still restricted to the epidermis are 
surrounded by basement membranes. Melanomas that have pene- 
trated into the dermis, however, no longer have basement mem- 
branes. “The conclusion, ” Krieg says, “is that, as long as you have 
the basement membrane, you are probably protected from metas- 
tasis.” 
Krieg and his colleagues used both electron microscopy and anti- 
bodies to probe the structures of basement membranes around nevo- 
cytic nevi, Spitz nevi, and malignant melanomas. The researchers 
found that the basement membranes around nevi, whether in the 
epidermis or dermis, appeared intact, although they were thinner 
than other basement membranes. The nevi membranes contained 
the typical basement membrane proteins, including collagen IV, 
laminin, and nidogen, but lacked collagen VII, a major component 
of the anchoring fibrils associated with other basement membranes. 
The composition of the basement membranes of malignant mela- 
nomas in the epidermis resembled those of the nevi. The lack of 
collagen VII and thus of anchoring fibrils may allow the nests of 
nevi and melanoma cells to bulge into the dermal stroma. At some 
point, however, melanomas that are invading the dermis also lose 
most of the other components of their basement membranes. 
Whether this happens because the malignant melanoma cells fail to 
make those proteins or because the cells secrete enzymes that de- 
stroy them is currently unknown. But however the loss occurs, the 
absence of an intact basement membrane could be an important 
factor in allowing melanoma cells to escape into the blood vessels 
and thus to other parts of the body. In addition, Krieg suggests that 
it may be possible to use the basement membrane composition of 
melanoma tumors to predict the prognoses of the patients, although 
more work will be needed to confirm this. 
